Poster: MPN-215 Outcomes of Myelofibrosis Patients Post Allogeneic-HSCT at the University of Southern California, a Retrospective Study

Given most of our patients were high/very high risks, achieving 3y-OS of 66.7% in primary and 55.6% in secondary MF since the time of transplant is appreciable. Interestingly, even with higher OS/EFS for JAK2V+ patients, the OS/EFS is lower for those who received a JAK2 inhibitor. This could be from the low sample size. Further studies are necessary.